VIPR1 antagonists(Vasoactive intestinal polypeptide receptor 1 antagonists), VIPR2 antagonists(Vasoactive intestinal polypeptide receptor 2 antagonists)

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [1]

Active Indication

Pancreatic Ductal AdenocarcinomaAdult Acute Myeloblastic Leukemia

Inactive Indication-

Originator Organization

Active Organization

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Structure/Sequence

Sequence Code 1116819179

100 Clinical Results associated with ANT308

100 Translational Medicine associated with ANT308

100 Patents (Medical) associated with ANT308

Literatures (Medical) associated with ANT308

International journal of molecular sciences

Chemical Modifications to Enhance the Drug Properties of a VIP Receptor Antagonist (ANT) Peptide

Article

Author: Waller, Edmund K. ; Li, Jian-Ming ; Lester, Christina ; Wang, Yuou ; Blakey, Simon B. ; Passang, Tenzin

Antagonist peptides (ANTs) of vasoactive intestinal polypeptide receptors (VIP-Rs) are shown to enhance T cell activation and proliferation in vitro, as well as improving T cell-dependent anti-tumor response in acute myeloid leukemia (AML) murine models. However, peptide therapeutics often suffer from poor metabolic stability and exhibit a short half-life/fast elimination in vivo. In this study, we describe efforts to enhance the drug properties of ANTs via chemical modifications. The lead antagonist (ANT308) is derivatized with the following modifications: N-terminus acetylation, peptide stapling, and PEGylation. Acetylated ANT308 exhibits diminished T cell activation in vitro, indicating that N-terminus conservation is critical for antagonist activity. The replacement of residues 13 and 17 with cysteine to accommodate a chemical staple results in diminished survival using the modified peptide to treat mice with AML. However, the incorporation of the constraint increases survival and reduces tumor burden relative to its unstapled counterpart. Notably, PEGylation has a significant positive effect, with fewer doses of PEGylated ANT308 needed to achieve comparable overall survival and tumor burden in leukemic mice dosed with the parenteral ANT308 peptide, suggesting that polyethylene glycol (PEG) incorporation enhances longevity, and thus the antagonist activity of ANT308.

Identification and characterization of vasoactive intestinal peptide receptor antagonists with high-affinity and potent anti-leukemia activity

Article

Author: Papadantonakis, Nikolaos ; Bruk, Nabute ; Wang, Shuhua ; Giver, Cynthia ; Chaudagar, Kiranj ; Sen-Majumdar, Anish ; Wang, Yuou ; Li, Yiwen ; Giver, Cynthia R. ; Das, Pankoj Kumar ; Li, Jian-Ming ; Waller, Edmund K. ; Sarkar, Srijon ; Cohen, Jamie ; Chen, Zihan ; Passang, Tenzin ; Waller, Edmund K

ABSTRACT:

Vasoactive intestinal peptide (VIP) is a neuropeptide involved in tumor growth and immune modulating functions. Previous research indicated that a VIP antagonist (VIPhyb) enhances T-cell activation and induces T-cell-dependent anti-leukemic activity in mice. We created a combinatorial library of VIPhyb C-terminal sequence variations to develop a more potent VIP-receptor (VIP-R) antagonist, hypothesizing that specific amino acid substitutions would improve receptor binding and plasma stability.In silicoscreening analyses identified sequences with improved docking scores predicting increased binding affinity to human VIP receptors VPAC1 and VPAC2. Fifteen peptides were synthesized and tested for their ability to potentiate activation of purified mouse and human T cells and enhance T cell-dependent anti-leukemia responses in murine models of acute myeloid leukemia. Treating C57Bl/6 mice engrafted with a C1498 myeloid leukemia cell line with daily subcutaneous injections of VIP-R antagonist peptides induced T cell activation resulting in specific anti-leukemia responses. Strikingly, the predicted binding affinity of the VIP-R antagonists to VIP receptors correlated positively with their ability to augment mouse T-cell proliferation and anti-leukemia activity. ANT308 and ANT195 emerged as top candidates due to their high predicted VIP-R binding, low EC50forin vitroT cell activation, and potent anti-leukemia activities. ANT308 decreased CREB phosphorylation, a downstream signaling pathway of the VIP receptor, and stimulated granzyme B and perforin expression in CD8+ T cells from AML patients. Combiningin silicomodeling,in vitroT cell activation properties, andin vivoanti-leukemia activity has identified promising VIP-R antagonist candidates for further development as novel immunotherapies for AML, especially for patients with relapsed disease.

News (Medical) associated with ANT308

27 Jan 2025

·www.prnewswire.com

Seeking Investors: First-in-Class Immunotherapeutics for Cancer

ATLANTA, Jan. 27, 2025 /PRNewswire/ -- Cambium Oncology is pleased to share that their lead drug candidate, ANT308, recently demonstrated outstanding single-agent efficacy and safety in preclinical studies. The drug is mutation-agnostic, and the company observes no toxicity-limiting dosages. In addition to their Fast-Track SBIR NIH grant recently being funded for $2.4M, they have received a significant investment from OEP Innovations of Taiwan. ANT308 is a FIRST-IN-CLASS immunotherapeutic with broad therapeutic potential across hematologic malignancies and solid tumors with the potential to enhance response rates in cancers that are resistant to other treatments. The intellectual property portfolio is expansive and solid. We have no debt. MULTIPLE PROOFS-OF-CONCEPT: Leukemia and Pancreatic Cancers (1)Leukemia ANT308 has shown strong single-agent anti-leukemia activity in 2 mouse models. (2) Pancreatic cancer ANT308 has shown synergistic effects with anti-PD-1 checkpoint inhibitors in 3 pancreatic cancer models. ANT308 is a proprietary small-molecule antagonist that blocks VIP-receptor signaling on human T cells, overcoming immune suppression in the tumor microenvironment. About Cambium Oncology: Founded in 2018, Cambium Oncology, LLC is a Delaware-based biotech company developing next-generation immuno-oncology therapeutics to activate the immune system and overcome tumor resistance. Its proprietary pipeline focuses on checkpoint inhibitors and immune-modulating agents for pancreatic cancer, melanoma, and leukemia. • Founder: Ned Waller, MD, PhD, has launched two biotech companies and is board certified in medical oncology and internal medicine. Since 1995 he has been a practicing physician with Emory Healthcare. He specializes in bone marrow transplants for acute leukemia, myelodysplastic syndrome, myeloproliferative neoplasms, lymphoma, aplastic anemia, sickle cell disease and in the management of graft-versus-host disease (GVHD). He is also an expert in CAR T-cell therapy. • CEO: Gary G. Altman, PhD, an industry veteran with buy-side and sell-side transaction experience in biotech investments and company acquisitions. • Website: Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements that involve known and unknown risks and uncertainties that may impact actual results. These statements are based on current expectations and are not guarantees of future performance. Media Contact: Gary Altman, [email protected], 305 484 7294, 13 Jan 2025 Logo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ImmunotherapyFast TrackCell TherapyClinical Study

100 Deals associated with ANT308

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatic Ductal Adenocarcinoma	Preclinical	United States	Cambium Oncology LLC	05 Aug 2024
Adult Acute Myeloblastic Leukemia	Preclinical	United States	Emory University	10 Dec 2022
Adult Acute Myeloblastic Leukemia	Preclinical	United States	Cambium Oncology LLC	10 Dec 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis